BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261112T100000
DTEND;TZID=America/New_York:20261112T120000
DTSTAMP:20261029T210718Z
CREATED:20260810T161933Z
LAST-MODIFIED:20261029T210718Z
UID:3281-1794477600-1794484800@lifescievents.com
SUMMARY:Intellia Therapeutics HAE Investor Event
DESCRIPTION:Join Intellia Therapeutics for a virtual key opinion leader (KOL) event featuring HAE experts Marc. A Riedl\, MD\, MS (University of California San Diego)\, and Danny M. Cohn\, MD\, PhD (Amsterdam UMC)\, both principal investigators in the Phase 3 HAELO trial of lonvo-z\, who will join company management to discuss: \n\nHereditary Angioedema (HAE) management in the U.S. and the unmet need that remains despite available treatments\nClinical data for lonvo-z\, including results from the Phase 3 HAELO trial\nPatient perspectives on lonvo-z\nIntellia’s commercial readiness efforts for lonvo-z\n\nLonvo-z has the potential to be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE. Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. HAE is a genetic disease characterized by overproduction of bradykinin\, which leads to recurring\, severe and unpredictable swelling in various parts of the body. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/isl03gk/.
URL:https://lifescievents.com/event/isl03gk/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/Events-Banners_2-6.png
END:VEVENT
END:VCALENDAR